ODP082 Bone mass and body composition analysis in transgender women: a 1 year follow up.

INTRODUCTION: Sex steroid hormones play a key role in bone health, however medical therapies for gender dysphoria lead to hormonal changes. PURPOSE: Understanding the changes in bone mass and body composition is extremely important, because this treatment will be carried out over a long period of time. METHODS: In a prospective study, we included 19 trans women (male-to-female trans persons) before and after 1 year of therapy with estrogen and cyproterone acetate. Bone densitometry model Hologic-Discovery performed at baseline and after 6, 12 months of therapy. All participants signed the TCLE, project approved by CEP-CAAE: 36823220.6. 0000. 0062. RESULTS: Analysis of 19 transgender women with a mean age of 25 years +/- 10 years. LS-BMD (lumbar spine) at initial time (0m) 1,070±0,155g/cm(2) and after 6 months (6m) 0,995±0,092g/cm(2) and 12 months (12m) after 1,020±0,096 g/cm(2), p=0,04; FN-BMD (Femur Neck) 0m= 1. 047±0.205g/cm(2); 6m= 0.917±0.127g/cm(2) and 12m= 0.909±0.120 g/cm(2); p=0. 01. TH-BMD (Total Hip) 0m= 1.100±0.162 g/cm(2); and 6m= 1. 021±0. 099g/cm(2); 12m= 1. 015±0.119g/cm(2); p=0. 02. About body composition: the percentage of body fat: 0m= 30.2±8. 0%, 6m= 31.3±7.9%; 12m= 33.2±10.2%; p=0.10; android/gynecoid ratio: 1. 00±0.26, 6m= 0.95±0.22; 12m= 1. 00±0.39; p=0,76, VAT mass (cm3) 411.8±252.1, 6m= 357.6±145.3, 12m= 395.5±167.7 p= 0,67 and Lean/Height(2) (kg/m(2)) 0m= 17. 03±2.98, 6m= 15.94±1.8, 12m= 16.74±2.10; p=0.46 and Appen. Lean/Height(2) (kg/m(2)) 7.89±1.67, 6m= 7.42±1.10 and 12m= 7.52±1. 01; p=0.90 Conclusion: In 1 year of hormone therapy with estrogen and cyproterone acetate, we found decrease in bone mass in the analyzed sites and no change in body fat and lean mass. Presentation: No date and time listed